Laboratory Corp. of America Holdings

  • Market Cap: Mid Cap
  • Industry: Miscellaneous
  • ISIN: US50540R4092
USD
261.48
-4.28 (-1.61%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Laboratory Corp. of America Holdings stock-summary
stock-summary
Laboratory Corp. of America Holdings
Miscellaneous
Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD). The LCD segment is an independent clinical laboratory business, which offers menu of frequently requested and specialty testing through an integrated network of primary and specialty laboratories across the United States. The CDD segment offers drug development services, and provides a range of drug research and development (R&D) and market access services to biopharmaceutical companies and medical device companies across the world. It serves a range of customers, including managed care organizations (MCOs), biopharmaceutical companies, governmental agencies, physicians and other healthcare providers.
Company Coordinates stock-summary
Company Details
358 S MAIN ST , BURLINGTON NC : 27215-5837
stock-summary
Tel: 1 336 22911271 336 4365076
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 153 Schemes (42.25%)

Foreign Institutions

Held by 341 Foreign Institutions (20.08%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Adam Schechter
President, Chief Executive Officer, Director
Mr. Peter Neupert
Lead Independent Director
Ms. Kerrii Anderson
Independent Director
Mr. Jean-Luc Belingard
Independent Director
Mr. Jeffrey Davis
Independent Director
Dr. D. Gary Gilliland
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
3,527 Million
(Quarterly Results - Jun 2025)
Net Profit:
238 Million
stock-summary
Industry

Miscellaneous

stock-summary
Market cap

USD 23,306 Million (Mid Cap)

stock-summary
P/E

28.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

1.06%

stock-summary
Debt Equity

0.60

stock-summary
Return on Equity

9.42%

stock-summary
Price to Book

2.75